Orano Group subsidiary Orano Med, a developer of targeted alpha therapies for oncology, inaugurated the expansion of its main research and development center located in Plano, Texas. The facility is used in the development of radiopharmaceuticals and for conducting preclinical research focused on targeted alpha therapies using lead-212, an alpha-emitting radioisotope that has shown promise in treating various types of cancer.